Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma who have undergone complete resection. Update October 2022

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma who have undergone complete resection. Update October 2022. Oncology Fact Sheet Nr. 99.

[thumbnail of Oncology Fact Sheet Nr.99_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
146kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WR Dermatology
Language:	English
Series Name:	Oncology Fact Sheet Nr. 99
Deposited on:	13 Jun 2022 10:04
Last Modified:	17 Oct 2022 12:46

Repository Staff Only: item control page